Regulations.gov document
Attachment 13 Real life experience recurrence rate at 3 years with Hexvix re…
Supporting & Related Material · FDA-2022-P-2644 · posted Oct 25, 2022
Key facts
| Document ID | FDA-2022-P-2644-0015 |
|---|---|
| Title | Attachment 13 Real life experience recurrence rate at 3 years with Hexvix re Reclassification Petition from Karl Storz SE and Co KG |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2022-P-2644 |
| Posted | Oct 25, 2022 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: